Piper Sandler reiterated their buy rating on shares of Proteostasis Therapeutics (NASDAQ:PTI) in a research note published on Monday morning, TipRanks reports. Piper Sandler currently has a $4.00 target price on the stock.
PTI has been the topic of a number of other reports. HC Wainwright reiterated a buy rating and issued a $8.00 price objective on shares of Proteostasis Therapeutics in a research report on Monday, December 23rd. Zacks Investment Research upgraded Proteostasis Therapeutics from a hold rating to a buy rating and set a $1.00 price objective on the stock in a research report on Wednesday, November 13th. ValuEngine upgraded Proteostasis Therapeutics from a hold rating to a buy rating in a research report on Friday, January 3rd. Finally, Piper Jaffray Companies reiterated a buy rating and issued a $4.00 price objective on shares of Proteostasis Therapeutics in a research report on Tuesday, December 17th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $6.20.
Shares of PTI opened at $1.54 on Monday. The firm has a market capitalization of $92.54 million, a price-to-earnings ratio of -1.20 and a beta of 0.38. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.89 and a current ratio of 6.89. The business’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.49. Proteostasis Therapeutics has a 52 week low of $0.61 and a 52 week high of $4.72.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. National Asset Management Inc. bought a new position in Proteostasis Therapeutics in the 4th quarter valued at $37,000. Squarepoint Ops LLC lifted its stake in shares of Proteostasis Therapeutics by 62.4% in the 3rd quarter. Squarepoint Ops LLC now owns 44,569 shares of the company’s stock valued at $38,000 after purchasing an additional 17,120 shares during the period. 9258 Wealth Management LLC acquired a new position in shares of Proteostasis Therapeutics in the 4th quarter valued at $49,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Proteostasis Therapeutics in the 4th quarter valued at $239,000. Finally, Oxford Asset Management LLP lifted its stake in shares of Proteostasis Therapeutics by 243.8% in the 4th quarter. Oxford Asset Management LLP now owns 495,807 shares of the company’s stock valued at $1,130,000 after purchasing an additional 351,575 shares during the period. Hedge funds and other institutional investors own 22.19% of the company’s stock.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study.
Featured Story: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.